Cargando…
Determining the Clinical Utility of 16S rRNA Sequencing in the Management of Culture-Negative Pediatric Infections
The use of 16S rRNA sequencing in culture-negative infections has improved identification of bacterial pathogens in select scenarios, but its clinical impact requires further elucidation, especially in the pediatric population. This retrospective study aims to determine the clinical utility of 16S r...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8868208/ https://www.ncbi.nlm.nih.gov/pubmed/35203762 http://dx.doi.org/10.3390/antibiotics11020159 |
_version_ | 1784656211525763072 |
---|---|
author | Lim, Peter Paul C. Stempak, Lisa M. Malay, Sindhoosha Moore, LeAnne N. Cherian, Sree Sarah S. Desai, Ankita P. |
author_facet | Lim, Peter Paul C. Stempak, Lisa M. Malay, Sindhoosha Moore, LeAnne N. Cherian, Sree Sarah S. Desai, Ankita P. |
author_sort | Lim, Peter Paul C. |
collection | PubMed |
description | The use of 16S rRNA sequencing in culture-negative infections has improved identification of bacterial pathogens in select scenarios, but its clinical impact requires further elucidation, especially in the pediatric population. This retrospective study aims to determine the clinical utility of 16S rRNA sequencing on the clinical management of pediatric culture-negative infections in our institution. Significant clinical utility was identified in 30 (40.5%) of 74 clinical samples (p < 0.0001). Of all specimens, pulmonary samples yielded the most clinical utility (n = 9, 30%), followed equally by joint fluid (n = 6, 20%) and bone (n = 6, 20%), with no difference between fluid and fresh tissue specimens (p = 0.346). Although the difference was not statistically significant (p = 0.4111), the overall use of broad-spectrum coverage was decreased. The median number of antibiotics was decreased from two to one (p < 0.0001) based on 16S rRNA sequencing results. The results suggest that 16S rRNA sequencing has a significant impact on decreasing the number of antibiotics used in the treatment of pediatric culture-negative infections. 16S rRNA sequencing performed on pulmonary specimens has the highest likelihood of identifying a pathogen compared to other specimen types. Additional cost–benefit analysis needs to be completed to further determine clinical benefit. |
format | Online Article Text |
id | pubmed-8868208 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88682082022-02-25 Determining the Clinical Utility of 16S rRNA Sequencing in the Management of Culture-Negative Pediatric Infections Lim, Peter Paul C. Stempak, Lisa M. Malay, Sindhoosha Moore, LeAnne N. Cherian, Sree Sarah S. Desai, Ankita P. Antibiotics (Basel) Article The use of 16S rRNA sequencing in culture-negative infections has improved identification of bacterial pathogens in select scenarios, but its clinical impact requires further elucidation, especially in the pediatric population. This retrospective study aims to determine the clinical utility of 16S rRNA sequencing on the clinical management of pediatric culture-negative infections in our institution. Significant clinical utility was identified in 30 (40.5%) of 74 clinical samples (p < 0.0001). Of all specimens, pulmonary samples yielded the most clinical utility (n = 9, 30%), followed equally by joint fluid (n = 6, 20%) and bone (n = 6, 20%), with no difference between fluid and fresh tissue specimens (p = 0.346). Although the difference was not statistically significant (p = 0.4111), the overall use of broad-spectrum coverage was decreased. The median number of antibiotics was decreased from two to one (p < 0.0001) based on 16S rRNA sequencing results. The results suggest that 16S rRNA sequencing has a significant impact on decreasing the number of antibiotics used in the treatment of pediatric culture-negative infections. 16S rRNA sequencing performed on pulmonary specimens has the highest likelihood of identifying a pathogen compared to other specimen types. Additional cost–benefit analysis needs to be completed to further determine clinical benefit. MDPI 2022-01-26 /pmc/articles/PMC8868208/ /pubmed/35203762 http://dx.doi.org/10.3390/antibiotics11020159 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Lim, Peter Paul C. Stempak, Lisa M. Malay, Sindhoosha Moore, LeAnne N. Cherian, Sree Sarah S. Desai, Ankita P. Determining the Clinical Utility of 16S rRNA Sequencing in the Management of Culture-Negative Pediatric Infections |
title | Determining the Clinical Utility of 16S rRNA Sequencing in the Management of Culture-Negative Pediatric Infections |
title_full | Determining the Clinical Utility of 16S rRNA Sequencing in the Management of Culture-Negative Pediatric Infections |
title_fullStr | Determining the Clinical Utility of 16S rRNA Sequencing in the Management of Culture-Negative Pediatric Infections |
title_full_unstemmed | Determining the Clinical Utility of 16S rRNA Sequencing in the Management of Culture-Negative Pediatric Infections |
title_short | Determining the Clinical Utility of 16S rRNA Sequencing in the Management of Culture-Negative Pediatric Infections |
title_sort | determining the clinical utility of 16s rrna sequencing in the management of culture-negative pediatric infections |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8868208/ https://www.ncbi.nlm.nih.gov/pubmed/35203762 http://dx.doi.org/10.3390/antibiotics11020159 |
work_keys_str_mv | AT limpeterpaulc determiningtheclinicalutilityof16srrnasequencinginthemanagementofculturenegativepediatricinfections AT stempaklisam determiningtheclinicalutilityof16srrnasequencinginthemanagementofculturenegativepediatricinfections AT malaysindhoosha determiningtheclinicalutilityof16srrnasequencinginthemanagementofculturenegativepediatricinfections AT mooreleannen determiningtheclinicalutilityof16srrnasequencinginthemanagementofculturenegativepediatricinfections AT cheriansreesarahs determiningtheclinicalutilityof16srrnasequencinginthemanagementofculturenegativepediatricinfections AT desaiankitap determiningtheclinicalutilityof16srrnasequencinginthemanagementofculturenegativepediatricinfections |